Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2018, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.
Cancer anorexia-cachexia syndrome or cancer cachexia is wasting of both adipose tissue and skeletal muscle in response to a malignant growth. Cachexia is present in the early stages of tumor growth before any signs or symptoms of malignancy. Symptoms include skeletal muscle wasting, weight loss and loss of appetite. Treatment includes appetite stimulants and change in life style.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 4, 12 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.
Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).
- The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cancer Anorexia-Cachexia Syndrome - Overview
Cancer Anorexia-Cachexia Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development
Abreos Biosciences Inc
Acacia Pharma Ltd
Aeterna Zentaris Inc
Aphios Corp
Energenesis Biomedical Co Ltd
Fountain Biopharma Inc
Incyte Corp
Lakewood-Amedex Inc
NGM Biopharmaceuticals Inc
Novartis AG
Paradigm Biopharmaceuticals Ltd
RaQualia Pharma Inc
Teijin Pharma Ltd
Vascular BioSciences
Viking Therapeutics Inc
XBiotech Inc
Zeria Pharmaceutical Co Ltd
Cancer Anorexia-Cachexia Syndrome - Drug Profiles
(formoterol fumarate + megestrol acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-380 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1889 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAR Peptide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENERGIF-706 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FB-704A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Foxo1-nRNA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-1510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-1940 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TCMCB-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEISARM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Xilonix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cancer Anorexia-Cachexia Syndrome - Dormant Projects
Cancer Anorexia-Cachexia Syndrome - Discontinued Products
Cancer Anorexia-Cachexia Syndrome - Product Development Milestones
Featured News & Press Releases
Mar 05, 2018: Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit
Sep 15, 2017: Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen
Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer
Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology
Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL
Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
Sep 02, 2014: XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer
Apr 17, 2014: XBiotech Announces Phase I/II Study Results in Lancet Oncology
Apr 24, 2013: XBiotech Enrolls First Patient In Phase III Pivotal Trial Of Xilonix
Oct 03, 2012: XBiotech Receives Fast Track Designation From FDA For Anti-Cachexia Drug Xilonix
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
Mar 30, 2012: XBiotech Announces FDA Approval To Launch Phase II Study Of Xilonix As Treatment For Cachexia In Subjects With Metastatic Cancers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Abreos Biosciences Inc, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Acacia Pharma Ltd, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Aeterna Zentaris Inc, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Aphios Corp, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Energenesis Biomedical Co Ltd, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Fountain Biopharma Inc, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Incyte Corp, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Lakewood-Amedex Inc, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by NGM Biopharmaceuticals Inc, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Novartis AG, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by RaQualia Pharma Inc, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Teijin Pharma Ltd, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Vascular BioSciences, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Viking Therapeutics Inc, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by XBiotech Inc, H1 2018
Cancer Anorexia-Cachexia Syndrome - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2018
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H1 2018
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H1 2018 (Contd..1), H1 2018
Cancer Anorexia-Cachexia Syndrome - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
